XML 134 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Collaborations, contracts and licensing agreements (Tables)
3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of deferred collaborations and contracts revenue The following table outlines the transaction price and the changes to the related liability balance:
Transaction PriceCumulative Collaboration Revenue RecognizedDeferred License Revenue
(in thousands)
Combined performance obligation$50,445 $38,850 $11,595 
Less contract asset(1,973)
Total deferred license revenue$9,622 
Summary of collaborations
Revenues are summarized in the following table:
Three Months Ended March 31,
20252024
(in thousands)
Revenue from collaborations and licenses
Acuitas Therapeutics, Inc.$504 $695 
Qilu Pharmaceutical Co., Ltd.812 244 
Non-cash royalty revenue
Alnylam Pharmaceuticals, Inc.448 593 
Total revenue$1,764 $1,532